First-Line Nivolumab Plus Ipilimumab With Chemotherapy for Metastatic NSCLC: The Updated Outcomes From CheckMate 9LA

Dual immunotherapy with first-line nivolumab plus ipilimumab has been reported to have durable efficacy in several metastatic solid tumors including NSCLC, melanoma, and renal cell carcinoma, among others.1 Clinical benefits have also been confirmed by pooled and exploratory analyses. However, evidence of immunotherapy for the intracranial activity of the brain metastatic populations with NSCLC is still limited especially from phase 3 trials. Paz-Ares et al.2 reported the 3-year updated outcomes of the CheckMate 9LA trial and revealed durable efficacy and safety profile of nivolumab plus ipilimumab with chemotherapy in patients with brain metastatic NSCLC.